| Literature DB >> 28544013 |
Zhe Liu1, Sayaka Nakashima1, Toshiyuki Nakamura1, Shintaro Munemasa1, Yoshiyuki Murata1, Yoshimasa Nakamura1.
Abstract
We investigated the molecular mechanisms involved in the angiotensin-converting enzyme (ACE) inhibition by (-)-epigallocatechin-3-gallate (EGCg), a major tea catechin. EGCg inhibited both the ACE activity in the lysate of human colorectal cancer cells and human recombinant ACE (rh-ACE) in a dose-dependent manner. Co-incubation with zinc sulfate showed no influence on the rh-ACE inhibition by EGCg, whereas it completely counteracted the inhibitory effect of ethylenediaminetetraacetic acid, a chelating-type ACE inhibitor. Although hydrogen peroxide was produced by the autoxidation of EGCg, hydrogen peroxide itself had little effect on the ACE activity. Conversely, the co-incubation of EGCg with borate or ascorbic acid significantly diminished the EGCg inhibition. A redox-cycling staining experiment revealed that rh-ACE was covalently modified by EGCg. A Lineweaver-Burk plot analysis indicated that EGCg inhibited the ACE activity in a non-competitive manner. These results suggested that EGCg might allosterically inhibit the ACE activity through oxidative conversion into an electrophilic quinone.Entities:
Keywords: (−)-epigallocatechin-3-gallate; angiotensin-converting enzyme; covalent modification; non-competitive inhibition
Mesh:
Substances:
Year: 2017 PMID: 28544013 DOI: 10.1002/jbt.21932
Source DB: PubMed Journal: J Biochem Mol Toxicol ISSN: 1095-6670 Impact factor: 3.642